Stifel analysts believe that the FDA's approval of exa-cel c...
Stifel analysts believe that the FDA's approval of exa-cel could significantly influence other Crispr-focused companies, potentially lessening risks for similar therapies, such as Editas Medicine's experimental cell therapy EDIT-301.
Crispr Therapeutics, Vertex Get FDA Approval for Breakthrough Gene-editing Treatment
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4026Followers
0Following
9023Visitors
Follow